Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences, Inc. (CTKB) reported third-quarter 2026 revenue of $53.2 million, compared with $52.3 million a year earlier. Gross profit increased to $31.2 million from $27.6 million, while net loss widened to $6.1 million from $5.5 million. For the first nine months, revenue was $145.5 million versus $139.4 million, and net loss was $37.1 million versus $22.5 million.
Operating cash use was $5.8 million for the nine months, compared with $3.9 million in 2025. As of September 30, 2026, cash, cash equivalents and restricted cash totaled $67.2 million, and marketable securities were $189.1 million.
In the Beckman Coulter litigation, a jury found for Cytek on three of four asserted patent claims; on the fourth, it found no literal infringement but infringement under the doctrine of equivalents. The jury awarded $56.11 million in past damages through September 30, 2025. The judgment is not final while post-trial motions remain pending; the company said the loss is reasonably possible but not probable and recorded no liability for the verdict. Both parties filed post-trial motions on October 13, 2026.
Cytek Biosciences, Inc. reported third-quarter 2026 revenue of $53.2 million, up 2% year over year. GAAP gross profit was $31.2 million, up 13%; GAAP gross margin was 59%, versus 53%, and adjusted gross margin was 61%, versus 55%. The adjusted measure excludes stock-based compensation and amortization of acquisition-related intangibles.
Operating expenses rose 8% to $39.6 million. Loss from operations was $8.4 million, compared with $9.2 million, while net loss was $6.1 million versus $5.5 million. Adjusted EBITDA was $0.7 million, compared with $2.5 million. Cash, cash equivalents, restricted cash and marketable securities totaled $256.3 million as of September 30, 2026, versus $262.0 million as of June 30, 2026.
Cytek maintained the midpoint of its 2026 revenue outlook and narrowed the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates. In a separate legal update, the company said a jury found in its favor on three of four asserted claims; on the fourth, it found no literal infringement but did find infringement under the doctrine of equivalents. Cytek filed post-verdict motions and intends to pursue available legal remedies, including a potential appeal.
Cytek Biosciences, Inc. (CTKB) is the issuer whose common stock is covered by an amended beneficial-ownership report from Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. Integrated Core Strategies reports 5,870,954 shares (4.5%); each of the other three reports 7,281,488 shares (5.6%), with shared voting and dispositive power and zero sole voting or dispositive power. The report says securities reported for the latter three are held by entities subject to voting control and investment discretion by Millennium Management and/or other investment managers, and says the disclosure alone is not an admission of beneficial ownership. Gil Raviv, Global General Counsel, and Israel A. Englander signed the amendment.
Cytek Biosciences, Inc. (CTKB) adopted amended and restated bylaws, effective September 23, 2026. The changes require additional information and representations from proponents of stockholder proposals and director nominees, including that they maintain record or beneficial ownership through the record date and meeting date and disclose information about proxy solicitation.
The bylaws also incorporate universal proxy rules, expand the chairperson’s authority to disregard non-compliant proposals and nominations, and add advance-notice compliance and disqualification procedures for director nominations at special meetings. Other updates address adjournment notices for virtual and remote meetings and procedures for preparing and making available the list of stockholders entitled to vote.
Cytek Biosciences, Inc. (CTKB) received a notice that officer Philippe Busque intends to sell 31,666 shares of common stock under Rule 144, with sales to be executed through Morgan Stanley Smith Barney LLC. The shares relate to a stock option exercise dated September 2, 2026. As context, common stock outstanding is listed as 129,983,253 shares as of September 2, 2026.
Cytek Biosciences, Inc. (CTKB) reported that a jury in the U.S. District Court for the District of Delaware returned a verdict in the patent infringement case brought by Beckman Coulter, Inc. The jury decided in Cytek’s favor on three of the four asserted patent claims, finding both noninfringement and invalidity for those three claims.
For the remaining claim, the jury found no literal infringement but did find infringement under the doctrine of equivalents, and awarded past damages of $20 million in lost profits and $36.11 million in royalties. Cytek stated that the verdict does not require any changes to its current product offerings or operations, and its spectral flow cytometry products remain available globally.
Cytek intends to file post-verdict motions challenging the doctrine-of-equivalents finding and the associated damages, and may pursue other post-trial remedies, including a possible appeal to the U.S. Court of Appeals for the Federal Circuit. The company also highlighted that additional costs, potential injunctive relief, or ongoing royalty obligations could result from further legal proceedings.
Cytek Biosciences, Inc. (CTKB) reported that President and CEO Wenbin Jiang exercised Restricted Stock Units into common stock on August 18, 2026. Four RSU vesting events resulted in the issuance of 120,095 shares of common stock. To cover related tax withholding obligations, 36,269 shares of common stock were withheld and surrendered at $4.67 per share. The RSU awards vest over four-year schedules with specified portions vesting each May 18, August 18, November 18, and March 10.
Cytek Biosciences, Inc. (CTKB) reported that Chief Financial Officer William D. McCombe exercised restricted stock units (RSUs) into 35,420 shares of common stock on August 18, 2026, through three RSU awards. In connection with these vestings, 11,904 shares of common stock were withheld and surrendered to Cytek to satisfy tax withholding obligations at a price of $4.67 per share. Each RSU represents a contingent right to receive one share of common stock, and the related awards vest over four years in specified installment schedules tied to May 18, August 18, November 18 and March 10 of various years.
Cytek Biosciences, Inc. (CTKB) director Glenn P. Muir reported an automatic conversion of 3,086 Restricted Stock Units into 3,086 shares of Common Stock on August 18, 2026. The RSU conversion price was $0.00 per share.
Following this transaction, Muir’s directly held RSU balance tied to this award is reported as 52,469 units, and his directly held Common Stock position from this transaction is 3,086 shares3 years in multiple tranches, including 2/36 of the total shares vesting on August 18, 2026, and additional 3/36 and 4/36 installments on specified dates thereafter, as long as the vesting conditions are met.
Cytek Biosciences, Inc. (CTKB) reported that director Michael Holder exercised restricted stock units into common stock. On August 18, 2026, 2,181 Restricted Stock Units converted into 2,181 shares of common stock, increasing his directly held common shares to 62,875 and reducing his Restricted Stock Units to 7,276. Each RSU represents a contingent right to receive one share of common stock, with the underlying RSU award vesting in scheduled tranches through at least August 18, 2025 as described in the vesting footnote.